Scienza e Tecnologia
PrecisionLife announces appointment of Colin Stubberfield as SVP Drug Discovery to lead development of its precision medicine programs
He joins from e-Therapeutics where he was Chief Research Officer, leading the Company's small molecule drug discovery projects. Colin has built virtual development models, bringing together resources from CROs and in collaboration with pharma partners. He has coordinated diverse teams in successful target identification/validation and drug discovery organizations, from large pharma to small biotechs, including UCB-Celltech, Oxford GlycoSciences, GSK and Wellcome.
"
The Company has analyzed over 30 chronic diseases, building an in-house pipeline of programs, with assets being developed for partnered R&D and spinout collaborations. Its near-term projects include R&D research studies into the long-term effects of coronavirus (long COVID), ALS, non-T2 asthma, COPD, and multi-target discovery and validation deals with major pharmaceutical companies.
PrecisionLife has raised additional finance to fund its expansion and anticipates a final close of its Series A investment round in the coming months. The financing is being co-ordinated by leading specialist life sciences investment banking and corporate advisory firm WG Partners LLP.
PrecisionLife is changing the way the world looks at predicting, preventing, and treating chronic disease. Our proven, patented combinatorial analysis platforms generate more insights from patient data than any other approach to understand the real drivers of disease biology at an unprecedented level of resolution.
These unique disease insights are enabling PrecisionLife and its partners to revolutionize drug discovery with novel targets for areas of unmet medical need, achieve more successful clinical development, and transform healthcare with accurate precision diagnostics, combinatorial risk models and clinical decision support tools. This approach will deliver a new age of better, more personalized therapy options to improve health, for everyone.
PrecisionLife is a private company headquartered near Oxford, UK and operations in Aalborg and Copenhagen, Denmark , Warsaw, Poland and Cambridge, MA , USA.
For more information see www.precisionlife.com
Follow us on LinkedIn (precisionlifeAI) and Twitter (@precisionlifeAI)
PrecisionLife
Steve Gardner , CEO
steve@precisionlife.com
T: +44 (0)1865 575170
Charles Consultants
Sue Charles
sue@charles-consultants.com
T: +44 (0)7968 726585
WG Partners LLP
David Wilson , Nigel Barnes ,
Parthiv Patel
T: +44 (0) 20 3705 9321